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findings provide further evidence for a high prevalence of VTE
in critically ill patients with SARS-CoV-2 infection. These find-
ings are important for identifying a high risk group for adverse
outcomes and to raise clinicians’ awareness of VTE risk
amongst critically ill COVID-19 patients.
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Prevalence and mortality in b-thalassaemias due to outbreak
of novel coronavirus disease (COVID-19): the nationwide
Iranian experience
In late December 2019, an ongoing outbreak of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
that was termed Coronavirus Disease 2019 (COVID-19), was
reported in Wuhan, China.1
A total of 3 018 681 patients have been reported globally
and 92 584 confirmed cases have been documented in Iran,
until April 29th, 2020. The death toll from the COVID-19 out-
break at that time was 207 973 worldwide, and 5877 in Iran.
Transfusion-dependent and non-transfusion-dependent
thalassaemia (TDT and NTDT) patients may have coexistent
comorbidities due to iron overload2,3 that can expose them
to a potentially higher risk of complications attributable to
COVID-19, compared to the normal population.4
Limited data about frequency and outcomes of infected
COVID-19 patients with thalassaemia are currently available
in the literature. In this study, the primary aim was to
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determine the prevalence, severity and mortality rate of
COVID-19 in patients with TDT and NTDT living in Iran.
Moreover, we evaluated the associated risk factors in this
vulnerable group of patients.
A multicentre, retrospective, cross-sectional study was
obtained across all comprehensive thalassaemia centres in
Iran, from January to 29 April 2020. All suspected and con-
firmed COVID-19 cases from a total of 15 950 TDT (regular
transfusion every 2–4 weeks) and 2 400 NTDT patients regis-
tered by the Iranian Ministry of Health (MOH) were evalu-
ated.
Epidemiological data, demographics, clinical characteristics
(type of thalassaemia, splenectomy status, and associated
complications), laboratory, imaging, and outcome data were
collected by analyzing patients’ electronic medical records.
A coronavirus test was performed based on the Berlin pro-
tocol by the real-time reverse-transcription polymerase chain
reaction (RT-PCR).5
Clinical and imaging manifestations for diagnosis of sus-
pected cases were: fever, shortness of breath, fatigue, dry
cough, and chest computed tomography scan suggestive of
SARS-CoV-2 pneumonia infection.
All patients were classified as mild, moderate, severe, and
critically ill according to the guidance issued by the National
Health Commission of China (accessed February, 2020).6
Hydroxychloroquine combined with lopinavir/ritonavir or
atazanavir were the suggested treatment regimens according
to guidelines issued by the Iranian MOH.
The study protocol was approved by the Ethical Commit-
tee of Shiraz University of Medical Sciences (Code:1399.228).
The patients or their legal guardians signed a consent form
to protect the confidentiality and their identity.
Qualitative and quantitative variables were compared
using Fisher’s exact test and the Mann–Whitney test respec-
tively between the two groups of confirmed COVID-19 cases
with the outcomes of recovery or death. COVID-19 preva-
lence and mortality rate were calculated in confirmed cases
and compared, by the chi-square test, with those reported in
the general Iranian population. A P value <005 was consid-
ered statistically significant.
Fifteen confirmed cases (12 TDT and 3 NTDT) and eight
symptomatic b-thalassaemia patients (6 TDT and 2 NTDT)
suspected of being infected with COVID-19 without per-
forming the test, were detected in a total of 18 350 Iranian
b-thalassaemia patients.
Detailed data of confirmed cases are presented in Table SI.
Clinical characteristics and laboratory data of confirmed and
suspected COVID-19 cases are summarized in Table I below.
Almost all the thalassaemia patients with COVID-19 were
from Northern and Southern Iran as well as the central part,
which were the epicentres for COVID-19 disease.
Seventeen patients (739%) had mild to moderate symp-
toms and recovered, while six patients died (261%, two
TDT and four NTDT). More than 60% of all patients had at
least one comorbidity (Table I).
The clinical and laboratory data were compared in RT-
PCR positive b-thalassaemia patients who recovered versus
those who deceased (Table II).
The two groups were comparable in nearly all variables
except for the thalassaemia type. Moreover, major underlying
diseases including diabetes, heart disease, hypertension, and
pulmonary artery hypertension showed a significantly higher
frequency in the deceased group compared to the recovered
group (100% vs. 273%; P = 0026). Eighty per cent of our
patients with confirmed COVID-19 were splenectomized but
splenectomy was not significantly associated with the fatal
outcome (II).
The prevalence of confirmed COVID-19 was 1101/10 000
in the general population compared to 817/10 000 in
patients with b-thalassaemia up to 29 April 2020
(P = 0246). On the other hand, at the same date, the mor-
tality rate was significantly higher in patients with b-thalas-
saemia (266%) compared to the general population (634%)
(P = 0001).
According to a COVID-19 webinar presented by the Euro-
pean Hematology Association, 51 patients with TDT and
COVID-19 have been reported from nine countries (https://
ehaweb.org/COVID-19/webinars.session 3; 16 April 2020).
Most of them presented mild to moderate respiratory symp-
toms (46 out of 51) and three out of five hospitalized
patients died.
A small cohort study from Northern Italy, which was the
epicentre for COVID-19 in Europe, experienced relatively
mild to moderate COVID-19 disease (11 cases: 10 with TDT
and one with NTDT) compared to the general population
and all infected thalassaemia patients recovered despite all of
them having associated comorbidities.7
Our survey is the first nationwide investigation that sys-
tematically evaluated the prevalence of COVID-19, the pres-
ence of comorbidities and the prognosis in patients with
TDT and NTDT in Iran.
Most of our patients showed mild to moderate disease, as
reported in Italy, but six cases developed severe symptoms
contributing to the patients’ mortality while no deaths were
reported in Italian patients with thalassaemias.7
The significantly higher mortality rate in COVID-19 tha-
lassaemic patients compared to the general Iranian popula-
tion may be attributed to the presence of additional risk
factors in patients with thalassaemias.4
Moreover, a significantly higher frequency of major under-
lying diseases in the deceased group compared to the recov-
ery group emphasizes the importance of adherence to iron
chelation regiment in thalassaemia patients.
No cases of paediatric or adolescent thalassaemia with
COVID-19 were observed in our study, which was similar
to fewer children being infected by COVID-19 in the general
population.8
One observational study reported subjects with blood group
A were at higher risk while subjects with blood group O were
associated with a lower risk for SARS-CoV-2 infection.9 Our
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Table I. Summary of clinical characteristics and laboratory data of confirmed and suspected COVID-19 cases in patients with b-thalassaemias.
Parameters COVID-19 (RT-PCR positive; n = 15) Suspected COVID-19 (n = 8)
Age (year), mean  SD, min–max 361  121, 22–66 396  903, 30–54
Sex (m/f) 7/8 7/1
Thalassaemia type (n, %) = =
TDT 12 (80) 6 (75)
NTDT 3 (20) 2 (25)
Splenectomy (yes) (n, %) 12 (80) 4 (571)
Serum ferritin (ng/ml)
Mean  SD 1725  2245 2847  3189
Median (min–max) 830 (225–8200) 2000 (545–9556)
(n, %) = =
≤2000 11(786) 4 (571)
>2000 3 (214) 3 (429)
Haemoglobin (g/l), mean  SD 89  68 84  144
White blood cell count (per µl), mean  SD 15 885  11 579 22 914  15 830
Platelet count (per µl), mean  SD 530 820  289 787 514 428  213 550
Heart or liver iron overload (moderate and severe) (n, %) 5 (333) 3 (375)
Hydroxycarbamide (yes) (n, %) 3 (20) 4 (50)
Comorbidities (yes) (n, %) 12 (80%) 5 (625)
Major underlying disease* 7 (467) 4 (50)
Symptoms (N, %) = =
Fever 10 (667) 3 (375)
Cough 9 (60) 2 (25)
Dyspnoea 4 (266) 2 (25)
Rhinorrhoea and sneezing 1 (66) NR
Sinusitis 1 (66) NR
Myalgia NR 1 (125)
Diarrhoea NR 1 (125)
Anosmia and hearing loss 1 (66) NR
Weakness in lower extremities 1 (66) NR
Condition = =
Recovered 11 (733) 6 (75)
Death 4 (266) 2 (25)
RT-PCR, reverse-transcription polymerase chain reaction; TDT, transfusion-dependent b-thalassaemia; NTDT, non-transfusion-dependent b-tha-
lassaemia; NR, not reported.
*Heart disease, diabetes, pulmonary artery hypertension, and hypertension.





N = 4 P value
Age (year), Median (min–max) 36 (22–66) 325 (30–60) 0949
Sex (m) (n, %) 5 (455) 2(50) >0999
Thalassaemia type (TDT) (n, %) 11 (100) 1(25) 0009
Splenectomy (yes) (n, %) 9 (818) 3 (75) >0999
Haemoglobin (g/l) median (min–max) 87 (79–97) 95 (82–99) 0226
Serum ferritin (ng/ml) >2000 (n, %) 3 (273) 0 >0999
White blood cell count (per µl), median (min–max) 12 300 (63–31 900) 12 000 (3775–34 360) >0999
Platelet count (per µl), median (min–max) 589 500 (840–848 000) 582 500 (147 000–965 000) 0808
Hydroxycarbamide (yes) (n, %) 1 (91) 2 (50) 0154
Heart or liver iron overload (moderate and severe) (n, %) 4 (364) 1 (25) >0999
Comorbidities (n, %) 8 (727) 4 (100) 0516
Major underlying disease* (n, %) 3 (273) 4 (100) 0026
*Heart disease, Diabetes, pulmonary artery hypertension, and hypertension.
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study showed a low frequency of blood group O among con-
firmed COVID-19 cases (13%, two out of 15).
In conclusion, our study showed a low number of b-tha-
lassaemia patients with COVID-19 that most of them devel-
oped mild to moderate disease and recovered but having
multiple comorbidities predisposed these patients to have a
severe disease and a significantly higher risk of mortality
compared to cases in the general population infected with
COVID-19. These findings provide objective evidence which
further variables should be taken into account in the com-
prehensive risk assessment and prognosis of thalassaemic
patients with COVID-19.
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